- Home
- WU vs AAPG Comparison
WU vs AAPG Comparison
Compare WU & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WU | AAPG |
|---|---|---|
| Founded | 1851 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.7B |
| IPO Year | 2006 | 2025 |
Fundamental Metrics
Financial Performance| Metric | WU | AAPG |
|---|---|---|
| Price | $9.35 | $27.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $8.75 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 7.8M | 4.2K |
| Earning Date | 02-03-2026 | 03-26-2026 |
| Dividend Yield | ★ 10.00% | N/A |
| EPS Growth | ★ 18.91 | N/A |
| EPS | ★ 2.32 | N/A |
| Revenue | ★ $4,100,500,000.00 | $54,524,554.00 |
| Revenue This Year | $0.13 | N/A |
| Revenue Next Year | $0.74 | $368.64 |
| P/E Ratio | $4.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.85 | $16.50 |
| 52 Week High | $11.95 | $48.45 |
Technical Indicators
Market Signals| Indicator | WU | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 54.30 | 39.93 |
| Support Level | $9.21 | $25.83 |
| Resistance Level | $9.43 | $29.37 |
| Average True Range (ATR) | 0.19 | 0.94 |
| MACD | -0.03 | -0.14 |
| Stochastic Oscillator | 41.49 | 25.99 |
Price Performance
Historical ComparisonAbout WU Western Union Company (The)
Western Union provides domestic and international money transfers through its global network of over 500,000 outside agents. The company handled almost 290 million transactions in 2024 and is the largest money transfer company in the world.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.